A UPLC-UV comparative fingerprint spectrum of Qizhi capsule and its establishment method and application
The control fingerprint of Qizhi Capsules was established through UPLC-UV technology, which solved the problem that the existing technology could not fully control the chemical information of the whole medicinal flavor of Qizhi Capsules, achieved overall quality control and efficacy stability, and simplified the detection process.
Patent Information
- Application Number
- CN202210411295.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-04-19
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2042-04-19
AI Technical Summary
The existing technology is difficult to effectively control the chemical information of Qizhi Capsules' full medicinal flavor, especially the Chinese medicine compound that contains plant medicines and animal medicines. The compound has a wide range of polarity, and the current quality standards cannot fully characterize Triangle, Hawthorn, Cassia seed, and Turtle. Other ingredients lead to difficulty in quality control.
UPLC-UV) technology is used to optimize the chromatographic column, optimize the chromatographic mobile phase elution procedure, integrate dual wavelength detection, and establish a UPLC-UV control fingerprint of Qizhi capsule covering the chemical chemical information of the group prescription, and Through the similarity evaluation method, 35 characteristic peaks and reference peaks were determined to achieve overall quality control.
The overall and whole-medicine flavor quality control of Qixie Capsules can be realized, and it can effectively characterize water-soluble and fat-soluble ingredients, animal medicine and plant medicine ingredients, ensuring the overall quality consistency and efficacy stability of Qixie Capsules, which is easy to operate and fast, precise.
Smart Images

Figure CN114839301B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a UPLC-UV control fingerprint spectrum of Qizhi capsule and an establishment method and application thereof, belonging to the technical field of quality control of traditional Chinese medicine. Background Art
[0002] The fingerprint of traditional Chinese medicine refers to the chromatogram or spectrum of a certain type or several types of components that are common and specific. Through the specificity of the fingerprint, the authenticity and source of the sample can be effectively identified; through the content or ratio of the main characteristic peaks of the fingerprint, the overall quality of the sample can be effectively controlled to ensure the relative stability of the sample quality. Compared with the existing identification of a single effective ingredient or an index component, the fingerprint technology of traditional Chinese medicine can basically reflect the overall profile of traditional Chinese medicine within a certain range, so that its quality control index is upgraded from the original determination of a single component to the detection of the intrinsic quality of the entire traditional Chinese medicine, realizing the comprehensive control of the overall substance and the comprehensive evaluation of the intrinsic quality of traditional Chinese medicine, and effectively ensuring the stability of the clinical efficacy of traditional Chinese medicine. In particular, the traditional Chinese medicine compound is composed of several or even more than ten traditional Chinese medicines, and has the characteristics of "monarch, minister, assistant and messenger" compatibility. Its clinical efficacy is the result of the combined action of multiple active ingredients of multiple traditional Chinese medicines. It is difficult to guarantee the quality and efficacy of the product by measuring the content of one or several components. Traditional Chinese medicine chromatographic fingerprint technology provides an effective method for the quality control of traditional Chinese medicine compound preparations. However, due to the complex chemical composition of traditional Chinese medicine compound, especially traditional Chinese medicine compound containing herbal medicine and animal medicine, the polarity range of compounds is wide, making it extremely challenging to establish a fingerprint that can comprehensively characterize the information of all medicinal ingredients of the compound.
[0003] Qizhi Capsule is a traditional Chinese medicine compound preparation produced by Harbin Traditional Chinese Medicine Factory No. 4 Co., Ltd. It is made of 9 traditional Chinese medicines, including astragalus, leech, peach kernel, Trillium, Curcuma, Polygonum multiflorum, Crataegus pinnatifida, Cassia seed, and Eupolyphaga sinensis. The current quality standard only conducts thin layer identification on astragalus, Curcuma, Hirudo, and Polygonum multiflorum and content determination on 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside (derived from Polygonum multiflorum), while the material basis information of Trillium, Crataegus pinnatifida, Cassia seed, and Eupolyphaga sinensis is not reflected in the quality standard. Therefore, the current quality standard cannot effectively control the quality of the preparation, and new quality control methods need to be established.
[0004] Chromatographic fingerprint technology provides a characterization method for establishing the chemical information of the whole medicinal flavor of Qizhi Capsule, which helps to achieve the overall quality control of the whole medicinal flavor of Qizhi Capsule. However, the formula of Qizhi Capsule is complex, containing both plant medicine and animal medicine, both whole powder of medicinal materials and aqueous extract of medicinal materials, both polar purine components and non-polar lipids and volatile components, and the polarity span of chemical components is large, and the content range is large. Therefore, it is technically difficult to establish a chromatographic fingerprint that can characterize the chemical information of the whole medicinal flavor of Qizhi Capsule. The present invention utilizes the high separation and high peak capacity performance of ultra-high performance liquid chromatography, optimizes the chromatographic column, optimizes the elution procedure of the chromatographic mobile phase, integrates dual-wavelength detection, and establishes a UPLC-UV control fingerprint of Qizhi Capsule covering the chemical information of the whole medicinal flavor of the formula, further optimizes the similarity evaluation method, and achieves the overall and whole medicinal flavor quality control of Qizhi Capsule. Summary of the invention
[0005] The technical problem to be solved by the present invention is to provide a UPLC-UV control fingerprint spectrum of Qizhi capsule and its establishment method and application in view of the above problems existing in the prior art, so as to overcome the shortcomings of the prior art.
[0006] In order to solve the above technical problems, the technical solution adopted by the present invention is:
[0007] A UPLC-UV reference fingerprint of Qizhi capsules, consisting of 35 characteristic peaks, with peak 18 as the reference peak, calculating the relative retention time of each characteristic peak and the reference peak, and the relative retention time should be within ±10% of the specified value, and the specified value is: 0.11-peak 1, 0.13-peak 2, 0.14-peak 3, 0.18-peak 4, 0.19-peak 5, 0.21-peak 6, 0.27-peak 7, 0.29-peak 8, 0.42-peak 9, 0.59-peak 10, 0.61-peak 11, 0.66-peak 12, 0.72-peak 13, 0. 74-peak 14, 0.75-peak 15, 0.87-peak 16, 0.98-peak 17, 1.00-peak 18, 1.13-peak 19, 1.17-peak 20, 1.21-peak 21, 1.43-peak 22, 1.44-peak 23, 1.58-peak 24, 1.68-peak 25, 1.74-peak 26, 1.76-peak 27, 1.77-peak 28, 1.79-peak 29, 1.85-peak 30, 1.93-peak 31, 2.06-peak 32, 2.07-peak 33, 2.12-peak 34, 2.14-peak 35.
[0008] In order to identify the main characteristic peaks of the UPLC-UV reference fingerprint of Qizhi Capsule, chemical reference substances were used for identification, among which peak 2 was hypoxanthine, peak 5 was allantoin, peak 15 was amygdalin, peak 17 was calycosin glucoside, peak 18 was 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside, peak 22 was aurantium dulcisin, and peak 31 was germacone.
[0009] The invention attributes the sources of characteristic peaks to medicinal materials, wherein peaks 7, 17, 19, 20, 21 and 23 are characteristic peaks of Astragalus, peaks 1, 2 and 32 are characteristic peaks of Leech, peaks 24, 26, 27, 28, 29 and 31 are characteristic peaks of Curcuma, peak 30 is characteristic peak of Tripterygium wilfordii, peaks 10, 14 and 15 are characteristic peaks of Prunus persica, peaks 4 and 16 are characteristic peaks of Crataegus pinnatifida, peaks 3 and 8 are characteristic peaks of Eupolyphaga sinensis, peaks 6 and 22 are characteristic peaks of Cassia seed, peaks 13, 18 and 25 are characteristic peaks of Polygonum multiflorum, and peak 9 is a newly generated peak.
[0010] The Qizhi capsule is prepared from the following raw materials in parts by weight: 100-400 parts of astragalus, 40-160 parts of leech, 75-300 parts of peach kernel, 75-300 parts of polygonum multiflorum, 55-220 parts of curcuma, 55-220 parts of trifoliate lanceolate, 62.5-250 parts of cassia seed, 62.5-250 parts of hawthorn and 15-60 parts of earthworm.
[0011] A method for establishing a UPLC-UV control fingerprint of Qizhi capsule comprises the following steps:
[0012] Take 0.5-5.0g of the fine powder of Qizhi Capsule, weigh it accurately, put it in a stoppered conical flask, accurately add 10-100mL of methanol of appropriate concentration, weigh it, extract it by ultrasonic for 10-100 minutes, let it cool, weigh it again, make up the lost weight, shake it well, filter it, and take the filtrate to get the test solution;
[0013] The test solution of the Qizhi capsule sample was separated by ultra-high performance liquid chromatography, and the chromatographic conditions were as follows: Waters ACQUITY UPLC HSS T3 column (2.1×100 mm, 1.8 μm), mobile phase acetonitrile-0.05-0.3% phosphoric acid aqueous solution, linear gradient elution, flow rate 0.2-0.5 mL / min, column temperature 20-40°C, injection volume 0.5-5 μL;
[0014] The linear elution gradient of the mobile phase is: 0-3 min, acetonitrile 1→4%; 3-4 min, acetonitrile 4→8%; 4-7 min, acetonitrile 8→11%; 7-18 min, acetonitrile 11→64%; 18-22 min, acetonitrile 64→100%; 22-24 min, acetonitrile 100%;
[0015] The detection was carried out by ultraviolet spectrum dual wavelength switching scanning method, and the detection wavelength was: 260nm for 0-5min and 210nm for 5-24min;
[0016] Take at least 10 batches of Qizhi Capsule samples, prepare test solutions respectively, collect fingerprints, import them into the Chinese medicine chromatographic fingerprint similarity evaluation system of the National Pharmacopoeia Committee, and generate control fingerprints.
[0017] In order to calibrate the retention time of the characteristic peaks of the UPLC-UV reference fingerprint of Qizhi Capsule, Peak 18 (2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside) with a medium retention time and a large peak area was used as the reference peak. The preparation method of the optimized reference solution was as follows: take an appropriate amount of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside reference substance and add 75% methanol to make a solution with a concentration of 40 μg / mL.
[0018] The method for dissolving the contents of Qizhi Capsule is to use 75% methanol to dissolve.
[0019] The UPLC-UV reference fingerprint of Qizhi capsule of the present invention is generated by preparing test sample solutions of 10 batches of Qizhi capsule samples, collecting UPLC-UV fingerprints, processing them by using the Chinese medicine chromatographic fingerprint similarity evaluation system of the National Pharmacopoeia Committee, and generating a UPLC-UV reference fingerprint of Qizhi capsule containing 35 common characteristic peaks.
[0020] Application of a UPLC-UV reference fingerprint of Qizhi Capsules in the overall quality control of Qizhi Capsules.
[0021] The 34 characteristic peaks other than peak 18 are used for similarity evaluation, and the similarity between the sample fingerprint and the control fingerprint shall not be less than 0.90.
[0022] After uniformly integrating the 34 characteristic peaks except Peak No. 18, the obtained spectrum was imported into the Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System of the State Pharmacopoeia Committee in AIA format for similarity calculation. Except for Peak No. 18, the similarity between the sample fingerprint and the control fingerprint should not be less than 0.90.
[0023] The beneficial effects of the present invention are:
[0024] (1) Qizhi Capsule is prepared from 9 kinds of traditional Chinese medicine, including both herbal medicine and animal medicine, and its active ingredients are extremely complex. Among them, the active ingredients of animal medicine leech and earthworm are water-soluble hypoxanthine, allantoin, polypeptide and other ingredients, while the active ingredients of Curcuma and Tripterygium are fat-soluble ingredients such as germazine. In addition, it also contains cyanogenic glycosides, flavonoid glycosides, styryl glycosides, anthraquinones, lipids, organic acids and other ingredients, which brings difficulties to the characterization of the chemical information of the whole medicine. The UPLC-UV reference fingerprint of Qizhi Capsule of the present invention, after comparison with reference substances and analysis of the origin of medicinal materials, shows that it can characterize water-soluble and fat-soluble components, animal and herbal medicine components, and components representing the raw materials of the formula, so that it can be used for the overall quality control of Qizhi Capsule.
[0025] (2) The UPLC-UV control fingerprint of Qizhi Capsule published by the present invention was applied to the quality evaluation of 10 batches of Qizhi Capsule samples, and the similarity of the fingerprints of each batch of samples was greater than 0.9, indicating that the batches of Qizhi Capsule had good consistency. It was applied to the quality analysis of Qizhi Capsule samples that exceeded the shelf life, and it was found that the similarity was significantly lower than 0.9, and the characteristic peaks of the fingerprints derived from hawthorn and zedoaria were significantly reduced or disappeared, indicating that the control fingerprint of the present invention can effectively control the quality of Qizhi Capsule.
[0026] (3) The UPLC-UV control fingerprint of Qizhi Capsule disclosed in the present invention can complete good separation and dual-wavelength switching scanning detection of ultraviolet spectrum within 24 minutes. Compared with other detection methods such as HPLC-UV method and TLC method, it can not only detect the characteristic chemical composition information of the whole medicinal taste of the formula, but also has the advantages of simple, fast and accurate operation, thus realizing the overall quality control of Qizhi Capsule and effectively ensuring the quality controllability and efficacy stability of Qizhi Capsule. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.
[0028] Figure 1 This is the UPLC-UV control fingerprint of Qizhi Capsule;
[0029] Figure 2 UPLC-UV fingerprints of 10 batches of Qizhi Capsules;
[0030] Figure 3 It is a comparison diagram of the UPLC-UV fingerprint of the Qizhi capsule sample that has exceeded the shelf life and the fingerprint of the control;
[0031] Figure 4 This is the medicinal material attribution diagram of the characteristic peaks of the UPLC-UV reference fingerprint of Qizhi Capsule;
[0032] Figure 5 This is the chemical component identification diagram of the characteristic peaks of the UPLC-UV reference fingerprint of Qizhi Capsule. DETAILED DESCRIPTION
[0033] In order to make the purpose, technical solution and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. The specific embodiments described here are only used to explain the present invention and are not used to limit the present invention.
[0034] Embodiment 1:
[0035] The method for establishing the UPLC-UV control fingerprint of Qizhi Capsule comprises the following steps:
[0036] 1. Preparation of test solution
[0037] Take 2.0 g of the fine powder of the Qizhi capsule sample, weigh it accurately, put it in a stoppered conical flask, add 20 mL of 75% methanol accurately, weigh it, extract it by ultrasonic for 30 minutes, let it cool, weigh it again, make up the lost weight with methanol, shake it well, filter it, and take the filtrate to obtain the product.
[0038] 2. Preparation of reference solution
[0039] Accurately weigh an appropriate amount of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside reference substance and add methanol to prepare a reference substance solution containing 100 μg per 1 mL as the reference solution.
[0040] 3. Chromatographic conditions
[0041] Chromatographic column: Waters ACQUITY UPLC HSS T3 column (2.1×100 mm, 1.8 μm); mobile phase: acetonitrile as mobile phase A, 0.1% phosphoric acid solution as mobile phase B, linear gradient elution program as shown in the following table; detection wavelength: 260 nm for 0-5 min, 210 nm for 5-24 min; column temperature: 30° C.; flow rate: 0.4 ml / min.
[0042]
[0043] 4. Establishment of reference fingerprint
[0044] Take 10 batches of Qizhi capsule samples, prepare the test solution, collect the fingerprint, and import it into the Chinese Pharmacopoeia Committee Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System (2012 Edition) to generate the reference fingerprint (see Figure 1), 35 common peaks were selected as characteristic peaks of the control fingerprint. Peak 18 (2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside) in the control fingerprint of Qizhi Capsule has the largest peak area, good separation and moderate retention time. Peak 18 was selected as the reference peak, and the relative retention time of each characteristic peak compared with it was calculated for calibration of each common peak. The relative retention times of the 35 characteristic peaks were as follows: 0.11 (peak 1), 0.13 (peak 2), 0.14 (peak 3), 0.18 (peak 4), 0.19 (peak 5), 0.21 (peak 6), 0.27 (peak 7), 0.29 (peak 8), 0.42 (peak 9), 0.59 (peak 10), 0.61 (peak 11), 0.66 (peak 12), 0.72 (peak 13), 0.74 (peak 14), 0.75 (peak 15), 0.87 (peak 16), 0.98 (peak 17), 1. 00 (peak 18), 1.13 (peak 19), 1.17 (peak 20), 1.21 (peak 21), 1.43 (peak 22), 1.44 (peak 23), 1.58 (peak 24), 1.68 (peak 25), 1.74 (peak 26), 1.76 (peak 27), 1.77 (peak 28), 1.79 (peak 29), 1.85 (peak 30), 1.93 (peak 31), 2.06 (peak 32), 2.07 (peak 33), 2.12 (peak 34), 2.14 (peak 35).
[0045] Embodiment 2:
[0046] Application of UPLC-UV reference fingerprint of Qizhi Capsule in overall quality control of Qizhi Capsule:
[0047] 1. Identification of characteristic peaks of UPLC-UV fingerprint spectrum of Qizhi capsule sample:
[0048] Ten batches of Qizhi capsule samples were taken, and the test solutions were prepared respectively. The fingerprints were collected and imported into the Chinese Pharmacopoeia Committee Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System (2012 Edition). The fingerprints were compared with the UPLC-UV reference fingerprints of Qizhi capsules to identify the characteristic peaks in the sample fingerprints. The results showed that the fingerprints of each batch of Qizhi capsule samples contained 35 characteristic peaks in the reference fingerprints (see Figure 2 ).
[0049] 2. Calculation of similarity of UPLC-UV fingerprints of Qizhi capsule samples:
[0050] The peak area of peak 18 (2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside) in the fingerprint of Qizhi Capsule is the largest, but since it accounts for 30% of the total peak area, it is not conducive to the overall evaluation of the fingerprint similarity. The fingerprint similarity calculation of the other 34 common peaks except peak 18 is carried out. The peak area difference of each peak is small, which is conducive to the overall quality control of Qizhi Capsule. The fingerprints of 10 batches of Qizhi Capsule samples were collected. Except for peak 18, the other 34 common peaks were uniformly integrated, and the obtained spectra were imported into the Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System (2012 Edition) of the National Pharmacopoeia Committee in AIA format for similarity calculation. The results showed that the similarity of the fingerprints of each batch of Qizhi Capsule samples compared with the control fingerprint was greater than 0.9, as shown in Table 1.
[0051] Table 1 Similarity between the UPLC-UV fingerprint of Qizhi capsule sample and the control fingerprint
[0052]
[0053]
[0054] 3. Calculation of similarity of UPLC-UV fingerprints of Qizhi capsule samples that have exceeded their shelf life:
[0055] Take the expired Qizhi capsule sample (batch number 190101), prepare the test solution, collect the fingerprint, import it into the Chinese Pharmacopoeia Committee Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System (2012 Edition), and compare it with the UPLC-UV control fingerprint of Qizhi capsule (see Figure 3 , where S1 is the UPLC-UV fingerprint of the sample of Qizhi Capsule that has exceeded the shelf life, and S2 is the control fingerprint), the similarity is calculated, and the similarity between the fingerprint of the expired Qizhi Capsule sample and the control fingerprint is 0.846, which is less than 0.9. Comparing the characteristic peaks, it is found that in the fingerprint of the expired sample, the characteristic peaks of peaks 13, 16, 24, 27, and 29 derived from hawthorn and zedoaria are significantly reduced or disappeared. It shows that the control fingerprint of the present invention is composed of 35 characteristic peaks, and the similarity is set to be not less than 0.9, which can effectively control the quality of Qizhi Capsule.
[0056] Embodiment 3:
[0057] Feasibility analysis of reference peak selection:
[0058] In order to illustrate that the relative peak area of peak 18 (2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside) is too large, which is not conducive to the evaluation of the overall similarity of the fingerprint, the fingerprint of the expired Qizhi capsule sample (batch number 190101) was used as the evaluation object to compare the similarity before and after the exclusion of peak 18. The comparison between the fingerprint of the batch number 190101 Qizhi capsule and the control fingerprint is shown in Figure 3 , it can be seen in the figure that peaks 13, 16, 24, 27, and 29 are not detected or only detected in trace amounts in the batch of Qizhi capsule samples. Obviously, due to the batch of samples exceeding the shelf life, the intensity of the characteristic peaks of the fingerprint spectrum is significantly reduced, and the due clinical efficacy cannot be guaranteed. When the No. 18 peak is not excluded, the similarity of the fingerprint spectrum of the batch of samples reaches 0.97, and the similarity of the fingerprint spectrum of the batch of samples after excluding the No. 18 peak is 0.846, which is lower than 0.9, and is significantly related to the significant reduction or disappearance of the characteristic peaks of No. 13, 16, 24, 27, and 29. It is obviously reasonable to calculate the similarity of the fingerprint spectrum with the other 34 characteristic peaks excluding the No. 18 peak, which is conducive to the overall quality control of Qizhi capsule. Therefore, the present invention uses 34 common peaks other than the No. 18 peak as similarity evaluation indicators, and limits the comparison similarity with the control fingerprint spectrum to be not less than 0.9, which can effectively control the overall quality of Qizhi capsule. It should be noted that the control of Peak 18 has been controlled in the content determination item of the quality standard. This reference fingerprint spectrum, as an improvement of the original quality standard, more comprehensively controls the quality of Qizhi Capsules.
[0059] Embodiment 4:
[0060] The medicinal material attribution of the characteristic peaks of the UPLC-UV fingerprint of Qizhi Capsule:
[0061] In order to illustrate that the UPLC-UV reference fingerprint of Qizhi Capsule can characterize the representative chemical components of each raw material of the prescription, the source of the characteristic peaks was attributed and analyzed.
[0062] 1. Preparation of the test solution of Qizhi capsule sample:
[0063] Take a sample of Qizhi Capsule and prepare a test solution of Qizhi Capsule sample according to the test solution preparation method for control fingerprint detection.
[0064] 2. Preparation of the test solution of medicinal materials for the Qizhi Capsule formula:
[0065] Weigh the raw medicinal materials according to the prescription composition of Qizhi Capsule, and prepare the test solution of each raw medicinal material according to the preparation method of Qizhi Capsule and the test solution preparation method of the control fingerprint spectrum detection.
[0066] 3. Comparison of UPLC-UV fingerprint of Qizhi Capsule and fingerprint of prescription medicinal materials:
[0067] Take the Qizhi capsule test solution and each medicinal material test solution separately, and collect fingerprints according to the Qizhi capsule control fingerprint detection conditions (see Figure 4 , where A: Qizhi Capsule, B: He Shou Wu, C: Curcuma, D: Leech, E: Peach Kernel, F: Astragalus, G: Crataegus, H: Eupolyphaga, I: Tripterygium wilfordii, J: Cassia Seed), the retention time and UV spectrum of each characteristic peak were compared to determine the source of the medicinal materials of the characteristic peak, and the results are shown in Table 2. It shows that the characteristic peaks of the UPLC-UV fingerprint spectrum of Qizhi Capsule cover all the raw medicinal materials used to make the preparation, and can be used to control the overall quality of the preparation.
[0068] Table 2 Sources of characteristic peaks in the fingerprint of Qizhi Capsule and their medicinal materials
[0069]
[0070]
[0071] Embodiment 5:
[0072] Identification of characteristic peaks of UPLC-UV comparative fingerprint of Qizhi Capsule:
[0073] In order to identify the main characteristic peaks of the UPLC-UV reference fingerprint of Qizhi Capsule and illustrate that the characteristic peaks cover chemical components of different polarities, the characteristic peaks were identified using reference substances. As a result, 7 main characteristic peaks were identified, including hypoxanthine and allantoin with large polarity, amygdalin and calycosin with medium polarity, cassia bark with small polarity, and non-polar germacrone, indicating that the reference fingerprint can characterize the small molecule chemical components of various polarities in Qizhi Capsule.
[0074] 1. Preparation of reference solution
[0075] Accurately weigh appropriate amounts of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside, hypoxanthine, allantoin, amygdalin, calycosin glucoside, aurantium dulcis, and germacrone reference substances, and add methanol to make mixed reference substance solutions containing 100 μg, 40 μg, 20 μg, 100 μg, 20 μg, 20 μg, and 20 μg per 1 mL, respectively.
[0076] 2. Preparation of the test solution of Qizhi capsule sample
[0077] Take 2.0 g of the fine powder of the Qizhi capsule sample content, weigh it accurately, put it in a stoppered conical flask, add 20 ml of 75% methanol accurately, weigh it, extract it by ultrasonic for 30 minutes, cool it, weigh it again, make up the lost weight with methanol, shake it well, filter it, and take the filtrate to obtain it.
[0078] 3. Comparison of UPLC-UV fingerprint of Qizhi capsule and reference solution
[0079] Take the test solution and the mixed reference solution respectively, and collect the chromatogram according to the UPLC-UV reference fingerprint detection conditions of Qizhi Capsule, see Figure 5 , among which, 2: hypoxanthine, 5: allantoin, 15: amygdalin, 19: calycosin isoflavone glucoside, 22: 2,3,5,4'-tetrahydroxystilbene-2-O-β-D glucoside, 31: aurantiacin, 30: germacrone. According to the retention time and UV spectrum information of the chromatographic peaks, the common peaks of the fingerprint were assigned to chemical components. The results showed that among the common peaks of the UPLC-UV fingerprint of Qizhi Capsule, peak 2 was hypoxanthine, peak 5 was allantoin, peak 15 was amygdalin, peak 17 was calycosin isoflavone glucoside, peak 18 was 2,3,5,4'-tetrahydroxystilbene-2-O-β-D glucoside, peak 22 was aurantiacin, and peak 31 was germacrone.
[0080] Embodiment 6:
[0081] Optimization and methodological investigation of UPLC-UV comparative fingerprint detection method for Qizhi capsules:
[0082] In order to illustrate the feasibility of UPLC-UV fingerprint detection method for Qizhi capsule, the detection method was optimized and the methodological investigation was carried out.
[0083] 1. Optimization of detection methods
[0084] 1.1. Selection of detection wavelength
[0085] Due to the complex composition of Qizhi Capsule, the ultraviolet absorption of each component is quite different. The PDA detector was used to scan the sample in the wavelength range of 200-400nm. The scanning results showed that the chromatographic peak information was relatively rich in the range of 210nm-300nm; among them, at the wavelength of 260nm, the chromatographic peak information in the time period of 0-5 minutes was more; at the wavelength of 210nm, the chromatographic peak information in the time period of 5-24min was more, especially the amygdalin peak in the time period of 5-9min could be well detected, which was particularly important for the quality control of peach kernel; at the wavelength of 210nm, the chromatographic peak information in the time period of 20-24min was also more, mainly from the characteristic peaks of leeches, which was particularly important for the quality control of leeches. In order to obtain the chromatographic component information of different Chinese medicines in the compound as much as possible and avoid the loss of peak area information, the method of segmented switching wavelengths of 210nm and 260nm was determined, that is, 0-5min was detected at a wavelength of 260nm, and 5-24min was detected at a wavelength of 210nm.
[0086] 1.2. Selection of chromatographic column
[0087] The test solution of Qizhi capsule was taken to investigate the separation effects of Waters UPLC BEH C18 column (2.1×100mm, 1.7μm), Waters UPLC HSS T3 column (2.1×100mm, 1.8μm), and Waters UPLC COTEX T3 column (2.1×100mm, 1.8μm), and the fingerprints after preliminary optimization were determined. The results showed that the HSS T3 column had better retention of water-soluble components, the peak separation from 0 to 5min was relatively good, and the separation of other peaks was not much different, which could meet the requirements of fingerprint determination. Therefore, the Waters UPLC HSS T3 column was selected.
[0088] 1.3. Selection of extraction solvent
[0089] The test solution prepared with different extraction solvents was measured according to the chromatographic conditions under "2.1" to obtain the chromatogram. Comparison of the chromatograms revealed that 25% methanol and 50% methanol could not obtain good extraction for the fat-soluble component peak with a retention time of 20 to 24 minutes, while 75% methanol and 100% methanol could obtain good extraction for it; 100% methanol did not fully extract the water-soluble component peak with a retention time of 0 to 5 minutes, while 75% methanol could obtain good extraction for both water-soluble and fat-soluble components, so 75% methanol was selected as the extraction solvent.
[0090] 1.4. Selection of extraction time
[0091] The test solution prepared with different extraction time was measured according to the chromatographic conditions under "2.1", and the unit concentration peak area of 35 main chromatographic peaks was recorded for comparison. The comparison results showed that ultrasonic extraction for 30 minutes was significantly better than 15 minutes, and there was no significant difference with 45 minutes and 60 minutes. Ultrasonic extraction for 30 minutes can obtain good extraction of each peak, so ultrasonic extraction for 30 minutes was selected.
[0092] 1.5. Selection of sampling volume
[0093] The test solution prepared with different sampling amounts was measured according to the chromatographic conditions under "2.1". The unit concentration peak area of 35 main chromatographic peaks was recorded. The comparison results showed that when the sampling amount was 0.5g, 1.0g, and 2.0g, the sample extraction was relatively complete, while when the sampling amount was 0.5g and 1.0g, the absolute peak area was relatively small. When the sampling amount was 2.0g, sufficient extraction was obtained and the peak area was higher. Therefore, the sampling amount was determined to be 2.0g.
[0094] 2. Analytical methodology review
[0095] 2.1. Precision investigation
[0096] Take the Qizhi capsule sample (batch number 191202), weigh 2.0g of the content, accurately weigh, prepare the test solution, inject 5 injections continuously according to the fingerprint detection conditions, collect the fingerprint spectrum, and use 2,3,5,4'-tetrahydroxystilbene-2-O-β-D glucoside as the reference peak to calculate the relative retention time and relative peak area of each common peak. The results show that the relative retention time of each common chromatographic peak is RSD <1.0%, and the relative peak area of the common peak is RSD <10.0% except for peak 11, indicating that the method has good precision.
[0097] 2.2. Repeatability study
[0098] Take the same batch of Qizhi capsule samples (batch number 191202), weigh 2.0g of the content, accurately weigh, a total of 6 portions, prepare the test solution in parallel, measure according to the fingerprint detection conditions, and collect the fingerprint. Take 2,3,5,4'-tetrahydroxystilbene-2-O-β-D glucoside as the reference peak, and calculate the relative retention time and relative peak area of each common peak. The results show that the relative retention time of each common chromatographic peak is RSD <0.1%, and the relative peak area of the common peak is RSD <2.0% except for peaks 12 and 13, indicating that the method has good repeatability.
[0099] 2.3. Stability study
[0100] Take the same batch of test solution (batch number 191202) and inject it into the liquid chromatograph at 0, 2, 4, 6, 8, 10, and 12 hours according to the fingerprint detection conditions to collect fingerprints. Take 2,3,5,4'-tetrahydroxystilbene-2-O-β-D glucoside as the reference peak to calculate the relative retention time and relative peak area of each common peak. The results show that the relative retention time RSD of each common chromatographic peak is less than 0.1%, and the relative peak area RSD of the common peak is less than 3.6%, indicating that the test solution is stable within 12 hours.
[0101] Embodiment 7:
[0102] A UPLC-UV reference fingerprint of Qizhi capsules is composed of 35 characteristic peaks. Peak 18 is used as a reference peak. The relative retention time of each characteristic peak and the reference peak is calculated. The relative retention time should be within ±10% of a specified value. The specified values are: 0.11 (peak 1), 0.13 (peak 2), 0.14 (peak 3), 0.18 (peak 4), 0.19 (peak 5), 0.21 (peak 6), 0.27 (peak 7), 0.29 (peak 8), 0.42 (peak 9), 0.59 (peak 10), 0.61 (peak 11), 0.66 (peak 12), 0.72 (peak 13), 0.74 (peak 14). 4), 0.75 (peak 15), 0.87 (peak 16), 0.98 (peak 17), 1.00 (peak 18), 1.13 (peak 19), 1.17 (peak 20), 1.21 (peak 21), 1.43 (peak 22), 1.44 (peak 23), 1.58 (peak 24), 1.68 (peak 25), 1.74 (peak 26), 1.76 (peak 27), 1.77 (peak 28), 1.79 (peak 29), 1.85 (peak 30), 1.93 (peak 31), 2.06 (peak 32), 2.07 (peak 33), 2.12 (peak 34), 2.14 (peak 35).
[0103] After uniformly integrating the 34 characteristic peaks other than peak No. 18, the obtained spectrum is imported into the Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System of the National Pharmacopoeia Committee in AIA format for similarity calculation. The similarity between the sample fingerprint and the control fingerprint shall not be less than 0.90.
[0104] The Qizhi capsule is prepared from the following raw materials in parts by weight: 100-400 parts of astragalus, 40-160 parts of leech, 75-300 parts of peach kernel, 75-300 parts of polygonum multiflorum, 55-220 parts of curcuma, 55-220 parts of trifoliate lanceolate, 62.5-250 parts of cassia seed, 62.5-250 parts of hawthorn and 15-60 parts of earthworm.
[0105] Embodiment 8:
[0106] A method for establishing a UPLC-UV control fingerprint of Qizhi capsule comprises the following steps:
[0107] Take 0.5g of the fine powder of Qizhi Capsule, weigh it accurately, put it in a stoppered conical flask, add 10mL of 75% methanol accurately, weigh it, extract it by ultrasonic for 10 minutes, let it cool, weigh it again, make up the lost weight, shake it well, filter it, and take the filtrate to get the test solution;
[0108] The test solution of the Qizhi capsule sample was separated by ultra-high performance liquid chromatography, and the chromatographic conditions were as follows: Waters ACQUITY UPLC HSS T3 column (2.1×100 mm, 1.8 μm), mobile phase acetonitrile-0.05% phosphoric acid aqueous solution, linear gradient elution, flow rate 0.2 mL / min, column temperature 20°C, injection volume 0.5 μL;
[0109] The linear elution gradient of the mobile phase is: 0-3 min, acetonitrile 1→4%; 3-4 min, acetonitrile 4→8%; 4-7 min, acetonitrile 8→11%; 7-18 min, acetonitrile 11→64%; 18-22 min, acetonitrile 64→100%; 22-24 min, acetonitrile 100%;
[0110] The detection was carried out by ultraviolet spectrum dual wavelength switching scanning method, and the detection wavelength was: 260nm for 0-5min and 210nm for 5-24min;
[0111] Ten batches of Qizhi capsule samples were taken, and test solutions were prepared respectively. Fingerprints were collected and imported into the Chinese medicine chromatographic fingerprint similarity evaluation system of the National Pharmacopoeia Committee to generate control fingerprints.
[0112] Embodiment 9:
[0113] A method for establishing a UPLC-UV control fingerprint of Qizhi capsule comprises the following steps:
[0114] Take 5.0g of the fine powder of Qizhi Capsule, weigh it accurately, put it in a stoppered conical flask, add 100mL of 75% methanol accurately, weigh it, extract it by ultrasonic for 100 minutes, let it cool, weigh it again, make up the lost weight, shake it well, filter it, and take the filtrate to get the test solution;
[0115] The test solution of the Qizhi capsule sample was separated by ultra-high performance liquid chromatography, and the chromatographic conditions were as follows: Waters ACQUITY UPLC HSS T3 column (2.1×100 mm, 1.8 μm), mobile phase acetonitrile-0.3% phosphoric acid aqueous solution, linear gradient elution, flow rate 0.5 mL / min, column temperature 40°C, injection volume 5 μL;
[0116] The linear elution gradient of the mobile phase is: 0-3 min, acetonitrile 1→4%; 3-4 min, acetonitrile 4→8%; 4-7 min, acetonitrile 8→11%; 7-18 min, acetonitrile 11→64%; 18-22 min, acetonitrile 64→100%; 22-24 min, acetonitrile 100%;
[0117] The detection was carried out by ultraviolet spectrum dual wavelength switching scanning method, and the detection wavelength was: 260nm for 0-5min and 210nm for 5-24min;
[0118] Fifteen batches of Qizhi capsule samples were taken, and test solutions were prepared respectively. Fingerprints were collected and imported into the Chinese medicine chromatographic fingerprint similarity evaluation system of the National Pharmacopoeia Committee to generate control fingerprints.
[0119] The above shows and describes the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.
Claims
1. A method for establishing a UPLC-UV control fingerprint of Qizhi Capsule, characterized in that: The following steps are involved: Take 0.5-5.0g of the fine powder of Qizhi Capsule, weigh it accurately, put it in a stoppered conical flask, accurately add 10-100mL of methanol of appropriate concentration, weigh it, extract it by ultrasonic for 10-100 minutes, let it cool, weigh it again, make up the lost weight, shake it well, filter it, and take the filtrate to get the test solution; The test solution of the Qizhi capsule sample was separated by ultra-high performance liquid chromatography, and the chromatographic conditions were as follows: Waters ACQUITY UPLC HSS T3 column size was 2.1×100 mm, 1.8 μm, the mobile phase was acetonitrile-0.05-0.3% phosphoric acid aqueous solution, linear gradient elution, flow rate 0.2-0.5 mL / min, column temperature 20-40°C, injection volume 0.5-5 μL; The linear elution gradient of the mobile phase was as follows: 0-3 min, acetonitrile 1→4%; 3-4 min, acetonitrile 4→8%; 4-7 min, acetonitrile 8→11%; 7-18 min, acetonitrile 11→64%; 18-22 min, acetonitrile 64→100%; 22-24 min, acetonitrile 100%; The detection was carried out by ultraviolet spectrum dual wavelength switching scanning method, and the detection wavelength was: 260nm for 0-5min and 210nm for 5-24min; Take at least 10 batches of Qizhi capsule samples, prepare test sample solutions respectively, collect fingerprints, import them into the Chinese medicine chromatographic fingerprint similarity evaluation system of the National Pharmacopoeia Committee, and generate reference fingerprints; the preparation method of the reference 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside solution is as follows: take an appropriate amount of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside reference substance, add 75% methanol to make a solution with a concentration of 40 μg / mL; the dissolution method of the Qizhi capsule contents is to dissolve them in 75% methanol; Preparation of reference solution: Accurately weigh appropriate amounts of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside, hypoxanthine, allantoin, amygdalin, calycosin glucoside, aurantium dulcis, and germacrone reference substances, and add methanol to prepare mixed reference solutions containing 100µg, 40µg, 20µg, 100µg, 20µg, 20µg, and 20µg per 1mL, respectively.
2. The method for establishing a UPLC-UV control fingerprint of Qizhi Capsule according to claim 1, characterized in that: It consists of 35 characteristic peaks, with peak 18 as the reference peak. The relative retention time between each characteristic peak and the reference peak is calculated. The relative retention time should be within ±10% of the specified value. The specified value is: 0.11-peak 1, 0.13-peak 2, 0.14-peak 3, 0.18-peak 4, 0.19-peak 5, 0.21-peak 6, 0.27-peak 7, 0.29-peak 8, 0.42-peak 9, 0.59-peak 10, 0.61-peak 11, 0.66-peak 12, 0.72-peak 13, 0.74-peak 14, 0.75-peak 15, 0.87-peak 16, 0.98-peak 17, 1.00-peak 18, 1.13-peak 19, 1.17-peak 20, 1.21-peak 21, 1.43-peak 22, 1.44-peak 23, 1.58-peak 24, 1.68-peak 25, 1.74-peak 26, 1.76-peak 27, 1.77-peak 28, 1.79-peak 29, 1.85-peak 30, 1.93-peak 31, 2.06-peak 32, 2.07-peak 33, 2.12-peak 34, 2.14-peak 35.
3. The method for establishing a UPLC-UV control fingerprint of Qizhi Capsule according to claim 2, characterized in that: Peak 2 is hypoxanthine, peak 5 is allantoin, peak 15 is amygdalin, peak 17 is calycosin glucoside, peak 18 is 2,3,5,4'-tetrahydroxystilbene-2-O-β-D glucoside, peak 22 is aurantium dulcisin, and peak 31 is germacone.
4. The method for establishing a UPLC-UV control fingerprint of Qizhi Capsule according to claim 2, characterized in that: Peaks 7, 17, 19, 20, 21, and 23 are characteristic peaks of Astragalus, peaks 1, 2, and 32 are characteristic peaks of Leech, peaks 24, 26, 27, 28, 29, and 31 are characteristic peaks of Curcuma, peak 30 is characteristic peak of Tripterygium wilfordii, peaks 10, 14, and 15 are characteristic peaks of Prunus persica, peaks 4 and 16 are characteristic peaks of Crataegus pinnatifida, peaks 3 and 8 are characteristic peaks of Eupolyphaga sinensis, peaks 6 and 22 are characteristic peaks of Cassia seed, and peaks 13, 18, and 25 are characteristic peaks of Polygonum multiflorum.
5. The method for establishing a UPLC-UV control fingerprint of Qizhi Capsule according to claim 1, characterized in that: The Qizhi capsule is prepared from the following raw materials in parts by weight: 100-400 parts of astragalus, 40-160 parts of leech, 75-300 parts of peach kernel, 75-300 parts of polygonum multiflorum, 55-220 parts of curcuma, 55-220 parts of trifoliate lanceolate, 62.5-250 parts of cassia seed, 62.5-250 parts of hawthorn and 15-60 parts of earthworm.
6. Application of the method for establishing a UPLC-UV control fingerprint of Qizhi Capsule according to any one of claims 1 to 5 in the overall quality control of Qizhi Capsule.
7. The use according to claim 6, characterized in that: The 34 characteristic peaks other than peak 18 are used for similarity evaluation, and the similarity is calculated after unified integration. The similarity between the sample fingerprint and the control fingerprint should not be less than 0.90.
